Abstract
Introduction
Immune tolerance: a matter of life or death Fig. 1) [1, 2] .
The immune system responds to pathogen invasion with two temporarily separate but physically linked responses, mediated by different types of cells. The first response, termed innate immunity involves neutrophils, monocytes/macrophages and dendritic cells (DCs) in the periphery and microglia in the central nervous system (CNS). The innate response is rapid and based on the recognition of conserved pathogen-associated molecular patterns. In contrast, the adaptive response occurs later, following activation of T and B lymphocytes through specific receptors. In contrast to the innate response, adaptive immunity leads to the development of memory for a specific antigen. The successful elimination of most pathogens requires crosstalk between the innate and adaptive arms of the immune system. The innate immune system recognizes pathogen-associated molecular patterns through pattern-recognition receptors, such as Toll-like receptors (TLRs), which induce the release of pro-inflammatory cytokines, chemokines and free radicals, recruitment of inflammatory cells to the site of infection, and lysis of infected host cells by natural killer cells and cytotoxic T lymphocytes. The inflammatory process is vital to the survival of all complex organisms, and its functions play a profound role in health and disease. Although it is a localized protective response that serves to destroy the injurious agent, once the pathogen is eliminated, cells participating in innate and adaptive immunity have to be deactivated or eliminated, to re-establish tissue homeostasis. The accumulation and subsequent activation of leucocytes are central events in the pathogenesis of virtually all forms of inflammation. Uncontrolled activation of the immune system and the sustained production of inflammatory mediators lead to serious consequences for the host, such as tissue destruction, organ failure, even death. A further damage arises from potential autoimmune responses occurring during the inflammatory response, in which the immune cells and molecules that respond to pathogenderived antigens can also react to self-antigens. Therefore, in inflammatory/autoimmune diseases like multiple sclerosis, rheumatoid arthritis, and type 1 diabetes, the initial stages involve multiple steps that can be divided into two main phases: early events associated with initiation and establishment of autoimmunity to self-tissue components in peripheral lymphoid organs, and later events associated with the evolving immune and destructive inflammatory responses in the target tissue (

Progression of the autoimmune response involves the development of self-reactive T helper 1 (TH1) and TH17 cells, their entry into the target tissue, release of pro-inflammatory cytokines and chemokines and subsequent recruitment and activation of inflammatory cells (macrophages, neutrophils and mast cells). Production of inflammatory mediators, such as cytokines, matrix-degrading enzymes and free radicals by infiltrating cells and resident cells (synovial fibroblasts, osteoclasts, microglia cells) damages self-tissues. In addition, TH1-mediated production of autoantibodies by B cells, which form immune complexes and activate complement and neutrophils, contributes to autoimmune pathology and disease
propagation [2] . [3] . Moreover, adaptive immune system also helps to maintain immune tolerance during infection-induced immunopathology [4] . (Fig. 1 [4, 5] . In addition, Treg cells have been shown to be deficient in patients with rheumatoid arthritis, multiple sclerosis, type-1 diabetes and other autoimmune diseases [6] [7] [8] . [3] [4] [5] . [61] [62] [63] [64] [65] , type I diabetes mellitus [66, 67] , multiple sclerosis [68] [69] [70] , Sjogren's syndrome [71] , pancreatitis [72, 73] and uveoretinitis [74, 75] 
How to solve the problem of excessive inflammation: to counterbalance or to resolve
It is apparently clear that safe induction of antigen-specific longterm tolerance is critical for the control of autoreactive T cells on autoimmune diseases. In addition, the inflammatory process needs to be limited since excessive responses result in severe inflammation and collateral tissue damage. In general, inflammatory responses are self-controlled by anti-inflammatory mediators secreted by host innate immune system during the ongoing process, and the ability to control an inflammatory state depends on the local balance between pro-and anti-inflammatory factors
Intrinsic control of lymphocytes is exerted for example by central clonal deletion of self-reactive T cells in the thymus via apoptosis of immature self-reactive lymphocytes upon the exposure to selfantigen or activation-induced cell death of mature effector cells. Moreover, recent evidence demonstrate that the generation of antigen-specific regulatory T cells (Treg) with suppressive activity plays a critical role in the induction of peripheral tolerance
Moreover, numerous studies have demonstrated the therapeutic use of antigen-specific Treg cells in various models of autoimmune disorders
From a therapeutic point of view, the fact that the appearance of exacerbated inflammatory and autoimmune diseases is a consequence of an unbalance in pro-inflammatory factors versus anti-inflammatory cytokines, or in self-reactive TH1 cells versus Treg cells, becomes critical to the identification of agents that restore self-tolerance by regulating both unbalanced inflammatory and autoreactive responses. Non-steroidal anti-inflamma
Beneficial effect of neuropeptides in inflammatory disorders
Recent studies examining these neuropeptides have shown their relevance to health, proving a potentially crucial clinical significance in inflammatory and autoimmune diseases that upset the balance of body systems (Fig. 2). Treatment with VIP, ␣MSH, urocortin, adrenomedullin, cortistatin or ghrelin decreases the frequency, delays the onset and reduces the severity of various experimental models of sepsis [39, 50-55], collagen-induced arthritis [56-60], inflammatory bowel disease
. The therapeutic effects of these neuropeptides are associated with the reduction of the two main phases of these diseases. They impair early events that are associated with the initiation and establishment of autoimmunity to self-tissue components, as well as later phases that are associated with the evolving immune and destructive inflammatory responses. These neuropeptides reduce the development of selfreactive TH1 cells, their entry into the target organ, the release of pro-inflammatory cytokines and chemokines and the subsequent recruitment and activation of macrophages and neutrophils. This results in a decreased production of destructive inflammatory mediators (cytokines, nitric oxide, free radicals and matrix metalloproteinases) by infiltrating and resident (i.e. microglia or synoviocytes) inflammatory cells. In addition, the inhibition of the selfreactive TH1-cell responses gives to decreased titters in IgG2a autoantibodies, an antibody subtype that activates complement and neutrophils and contributes to tissue destruction.
Neuropeptides counterbalance the inflammatory response
The anti-inflammatory action of these neuropeptides is exerted at different levels of the innate immunity ( Fig. 2): (1) inhibition of phagocytic activity, free radical production, adherence and migration of macrophages [33, 36, 76] ; (2) [25, 28, 30, 35, 37, 39, 50, 51, 61, 62, 65, [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] 
reduction in the production of inflammatory cytokines (TNF␣, IL-12, IL-6 and IL-1␤) and various chemokines and down-regulation of the expression of inducible nitric oxide synthase and cycloxygenase 2 (COX2) and the subsequent release of nitric oxide and prostanglandin E2 by macrophages, DCs and microglia
Neuropeptides down-regulate Th1 responses
Although the mechanisms involved in the suppressive effects on TH1-cell responses of most of these neuropeptides are not fully elucidated, most data coming from VIP studies have clearly demonstrated that neuropeptides regulate the TH1/TH2 balance through various non-excluding mechanisms involving both direct actions on differentiating T cells and indirect regulation of APC functions (Fig. 2) [67, 77, 97-102]. First, VIP inhibits the production of the TH1-associated cytokine IL-12. Second, VIP induces CD86 expression in resting murine DCs, which is important for the development of TH2 cells. Third, VIP has been shown to promote specific TH2-cell recruitment by inhibiting CXC-chemokine ligand 10 (CXCL10) production and inducing CC-chemokine ligand 22 (CCL22) production, two chemokines that are involved in the homing of TH1 cells and TH2 cells, respectively. Fourth, VIP inhibits CD95 (FasL)-and granzyme B-mediated apoptosis of mouse TH2 but not of TH1 effector cells. Finally, VIP induces the TH2 master transcription factors c-MAF, GATA-3 and JUNB in differentiating murine CD4 + T cells, and inhibits T-bet, which is
required for TH1-cell differentiation. [113] [114] [115] [116] [117] [118] . In addition, it has been recently found in a genetic association between multiple-marker haplotypes of VIP receptor and rheumatoid arthritis susceptibility [117] . Finally, the significant reduced levels of VIP found in patients with lupus and autoimmune thyroditis have been related to the existence of high amounts of autoantibodies with VIPase activity [119] . These findings support the notion that reduced levels of neuropeptides, and deficiencies and/or mutations in their receptors and signalling make us more susceptible to suffer inflammatory and autoimmune diseases.
Neuropeptides generate regulatory T cells
Vasoactive intestinal peptide (VIP), ␣-melanocyte-stimulating hormone (␣MSH), urocortin (UCN), adrenomedullin (AM), ghrelin (GHR) and cortistatin (CST) are produced by T cells or macrophages in response to antigenic and inflammatory stimulation. These neuropeptides induce immune tolerance and inhibit the autoimmune response through different non-excluding mechanisms. (A) They decrease TH1-cell functions through direct actions on differentiating T cells, or indirectly by regulating dendritic cell (DC) functions. As a consequence, the inflammatory and autoimmune responses are impaired because the infiltration and activation of neutrophils and macrophages by interferon-␥ (IFN␥) and the production of complement-fixing IgG2a antibodies are avoided. (B) Neuropeptides inhibit the production of inflammatory cytokines, chemokines, free radicals (i.e. nitric oxide) and high-mobility group box 1 (HMGB1) by macrophages and microglia. In addition, they impair the costimulatory activity of macrophages on effector T cells, inhibiting the subsequent clonal expansion. This avoids the infiltration of leucocytes and the inflammatory response and the subsequent cytotoxicity against the target tissue. (C) Neuropeptides induce the new generation of regulatory T cells (Treg) that suppress activation of autoreactive T cells through a mechanism that involves production of interleukin-10 (IL-10) and transforming growth factor-␤ (TGF␤), and/or expression of the cytotoxic T lymphocyte-associated protein 4 (CTLA4). In addition, neuropeptides indirectly generate Treg through the differentiation of tolerogenic DCs. This effect contributes to the maintenance of an anti-inflam-
. Moreover, an altered expression of VIP receptors in T cells has been related to aberrant TH1 immunity in patients with multiple sclerosis and rheumatoid arthritis
Resolution of inflammation by endogenous lipid mediators
Human beings depend on the nutritional supply of two types of essential PUFAs, -3 and -6, which are enriched in fish oils. They are precursors of lipid mediators critical for a variety of cellular functions, including inflammation, nociception, renal function, reproductive activity, haemodynamics and blood clotting [120] . Most of the studies in the past were focused on the -6 [120, 121] . However, recent studies in animal models have proposed that they can also stimulate circuits to resolution of inflammation.
PUFA arachidonic acid (AA) as a classic precursor of bioactive PGs and LTs locally produced after tissue injury, microbial infection and surgical trauma through pathways involving cycloxygenases (COX-1 and COX-2) and lipoxygenases (LOX). AA-derived lipid mediators such as PGE2, PGD2 and LTs generated in the initial phase of inflammation have been classically involved in pro-inflammatory signalling and implicated in the pathogenesis of various inflammatory diseases
Lipoxins
Both PGE2 and PGD2 activate the expression of 15-LOX in neutrophils, which switches the mediator profile of these cells from LTB4 to lipoxins [122] . Lipoxins were the first mediators identified to have both anti-inflammatory and pro-resolving activities [123] . Lipoxins (LXA4 and LXB4) (Fig. 3) . [122] [123] [124] [125] . At the same time, lipoxins and ATLs stimulate the recruitment of monocytes by stimulating their chemotaxis and adherence without causing release of reactive oxygen species [126] [127] [128] , and promote the non-phlogistic phagocytosis of apoptotic neutrophils by macrophages [129, 130] . This is supported by a shift to an anti-inflammatory response by these mediators, because lipoxin, ATLs and their stable analogues inhibit the production and action of chemokines (i.e. IL-8) and TNF␣, whereas stimulate the anti-inflammatory cytokine TGF␤ [128, 131] . These effects seem to be mediated through the GPCR, LXA4 receptor (ALXR) also referred to as formyl peptide receptor-like 1 (FPRL1) and the subsequent inactivation of the transactivating pathways NFkB and AP1 [127, 129] .
Lipoxins and ATLs promote the resolution of inflammation by selectively stopping the entry of new PMNs to sites of inflammation that includes inhibition of chemotaxis of PMNs and their adhesion to and transmigration through endothelial cells and reduction of vascular permeability
As a consequence, these lipid mediators have been proven effective in various models of inflammatory diseases such as ischemia/reperfusion injury, inflammatory bowel disease, glomerulonephritis, allergic pleural edema, periodontitis, dermal inflammation and cystic fibrosis [131, 132] . Importantly, some of the beneficial effects ascribed to aspirin in various human diseases should be a consequence of the generation of ATL and subsequent promotion of inflammation resolution. [122, [140] [141] [142] [143] [144] [145] [146] [147] (Fig. 3) . [152] . In addition, RvE1 seems to bind to the GPCR receptor ChemR23 and inhibit NFkB signalling through a mechanism that involves phosphorylation rather than mobilization of calcium or cAMP [152] . [141, 142, 153] . [142, 143] [156] . Of note is the fact that PD1 is produced by Th2-skewed human peripheral blood mononuclear cells through a LOX-dependent mechanism [157] . This finding correlated with the early studies reporting that DHA modulates T-cell functions to favour a Th2 phenotype [157, 158] [160] . 
Resolvins and protectins
. Thus, they found that EPA generates the 18R E-series resolvins (resolvin E1 and resolvin E2) in the presence of aspirin during the spontaneous resolution phase of acute inflammation where specific cell-cell interactions occur (Fig. 3). They also elucidated that DHA generates the 17S D-series resolvins (resolvins D1 to D6) and protectin D1 (PD1) through interaction with leucocyte LOX, and alternatively, DHA forms the 17R D-series resolvins (AT-RvDs) in the presence of aspirin-acetylated COX2
RvE1 inhibits PMN transendothelial migration in vitro, reduces leucocyte infiltration in vivo, and inhibits DC migration and IL-12 production [140, 141, 147-150]. Moreover, RvE1 improved the survival of mice with colitis by reducing PMN recruitment and the expression of pro-inflammatory genes [151]. RvE1 can interact with the LTB4 receptor (BLT1) in leucocytes and attenuate LTB4-stimulated signals, acting as a partial agonist or antagonist
The other resolvins, especially RvD1, inhibit TNF␣-induced IL-1␤ production by microglia, reduce PMN infiltration into inflamed brain, skin and peritoneum, and are protective in a model renal ischemic injury
PD1, named as neuroprotectin D1 when produced in the neural tissue, also attenuates neutrophil transmigration in vitro and reduces in vivo PMN infiltration in models of peritonitis and cerebral stroke
. Attending to its name, PD1 has shown neuroprotective effects, promotes corneal epithelial cell wound healing and repair, and protects from lung damage by reducing airway inflammation and from kidney injury [153-155]. PD1 is the only lipid mediator derived from -3 PUFAs that showed direct immunomodulatory effects on T-cell function. PD1 inhibits the production of IFN␥ and TNF␣ by activated T cells and induces T cell apoptosis, suggesting that is down-regulating Th1-mediated responses
These findings outline the potential application of these lipid mediators in acute inflammatory diseases. However, their relevance in autoimmune disorders is still unknown, since research on the effect of lipid mediators in T-cell activity is scarce. This is probably an emerging field and further studies will determine whether we can extend their therapeutic use to autoimmune disorders. Similar to neuropeptides, the induction of immune tolerance by lipid mediators should be a critical point.
Therapeutic perspectives: rationale for using endogeneous neuropeptides and lipid mediators in immune disorders
Our body responds to an exacerbated inflammatory response by increasing the production of endogenous anti-inflammatory neuropeptides and lipid mediators, in an attempt to restore the immune homeostasis [161-167]. The findings reviewed above indicate that these neuropeptides act in a pleiotropic and in many cases in a redundant manner to regulate the balance between proinflammatory and anti-inflammatory factors, and between autoreactive TH1 cells and Treg cells. Lipid mediators such as LXs, Rvs and PDs each play an active role in controlling and programming resolution of inflammation and stimulating endogenous antiinflammatory and pro-resolving pathways. Based in these characteristics, anti-inflammatory neuropeptides and pro-resolving lipid mediators could represent feasible therapeutic agents in the treatment on immune diseases, such as rheumatoid arthritis, multiple sclerosis or Crohn's disease, characterized by a double component, inflammatory and autoimmune.
Advantages of using endogenous neuropeptides and lipids
From a therapeutic point of view, the wide spectrum of action of these endogenous mediators represents an advantage versus agents directed only against one component of these diseases. In addition, the promotion of an active program of inflammation resolution by lipid mediators is therapeutically attractive because the
Cell-based therapy
An important aspect for translational medicine is the induction of Treg cells by neuropeptides. This has not only been crucial to a better understanding of the immunomodulatory action of neuropeptides, but has also supposed the proposal of a new cellbased strategy for the treatment of immune disorders where tolerance restoration is needed. Considerable effort is recently focused on the use of antigen-specific Treg cells generated ex vivo to treat autoimmune diseases, transplantation and asthmatic
disorders [4] . The [172, 173] [4] [175, 176] . Perhaps even more important is work towards improving neuropeptide delivery to target tissues and cells while protecting it against degradation. Different strategies being tested under experimental conditions include neuropeptide gene delivery or the insertion of VIP into micelles or nanoparticles [66, 71, [177] [178] [179] [180] 
Neuropeptides could be one of these endogenous growth factors involved in the generation/expansion of Treg cells. In fact, neuropeptides induce the generation of self-peptides-specific Treg cells from otherwise conventional T cells in vitro. These cells prevent very efficiently the progression of experimental autoimmune diseases by suppressing the systemic autoantigen-specific T-and B-cell responses and the tissue-localized inflammatory response. On the other hand, the capacity of certain classes DCs to induce Treg cells makes them attractive for the expansion/generation of antigen-specific Treg cells ex vivo, or alternatively, for their use in vivo as therapeutic cells that restore immune tolerance by inducing Treg cells in the host
. In this sense, VIP-induced tolerogenic DCs pulsed with self-antigens have been shown to ameliorate the progression of rheumatoid arthritis, EAE and inflammatory bowel disease [106, 174]. This effect is mainly mediated through the generation of antigen-specific Treg cells in the treated animal. Probably, the most important issue that the cell-based therapy with neuropeptide-induced Treg cells or tolerogenic DCs needs to resolve is to determine the necessity of antigen specificity. Whereas polyclonal Treg cells might function in allograft transplantation and autoimmunity in lymphopaenic (i.e. systemic lupus eritematous) or inflammatory bowel disease settings, in other autoimmune disorders antigen-specific Treg cells are most effective
